China Resources Pharmaceutical Group Limited (SEHK:3320) is looking for mergers and acquisitions. Ran Tao, Chairman of CR Boya Bio said, "On top of the M&A, we focus on the innovative fields and technology platforms based on the consolidation of the existing advantageous business, to accelerate innovation and transformation, optimize the business structure and promote industrial upgrading. Han has also made some introductions to the strategy, and I will focus on some of our corresponding segments.

As I mentioned earlier, China Resources Pharmaceutical will take Boya Bio as the platform for our blood products industry, so we will continue to promote the development of this industrial platform. We are constantly looking for integration targets because there are still some targets and some opportunities in this market. We are constantly looking for them, hoping to seize the opportunity to accelerate the acquisition of licenses and the expansion of plasma stations, and to continuously expand and strengthen the blood products segment through internal development and external mergers and acquisitions".

Ran Tao added, "From the aspect of chemical drugs, we mainly focus on ingredients, polypeptide chemical drugs, chemical innovation drugs and high-end formulations to increase the outward M&A efforts. At the same time, we continue to expand our industry chain through mergers and acquisitions. In addition, we are also actively exploring the acquisition of [Pro-Tech] technology platforms, including small molecule inhibitors and other such new areas of expansion".